StockTipsArenaBeta

BUY Lupin Limited — Aditya Agarwal, Coheron Brokers

BUYLupin Limited
Lupin share price target & all analyst calls

byAditya Agarwal, Coheron BrokersHorizon: NA (inferred Swing (≤2wk))22 Oct 2026via Business Today

Entry₹1,937.4Inferred
Target₹2,100
Total upside +8.39%
Stop lossNot given
CMP₹1,919.7Just now
Active-0.91%+9.39%upside left 13d left
Follow Aditya Agarwal for new calls(32% target hit, 19 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 133 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 1:52 pm IST
3 supporting2 neutral1 opposing
Supports the BUY call (3)

Lupin gets US FDA nod for vitamin K injection with $52 million US market

NewsCnbc-Tv18·8 Oct · 2w ago

(opens in new tab)

Lupin received U.S. FDA approval for its Phytonadione Injectable Emulsion, USP.

BSE · Company Update·8 Oct · 2w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·22 Sept · 1mo ago

Neutral / worth noting (2)

Q2 FY27 results scheduled — board meets 03 Nov 2026

BSE · Board Meeting·In 12 days

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3d ago

(opens in new tab)
Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·22 Oct · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Aditya Agarwal, Coheron Brokers

Every call and its outcome